“`html
On October 17, 2025, UBS reiterated a Neutral recommendation for Rentokil Initial (OTCPK:RKLIF). The average one-year price target is $5.77/share, indicating a potential upside of 10.14% from the latest closing price of $5.24/share.
Projected annual revenue for Rentokil Initial is $5,822 million, a 5.20% increase, with a projected annual non-GAAP EPS of 0.28. Currently, 45 funds report positions in the company, a decrease of 6.25% from the last quarter, while total institutional shares owned increased by 3.04% to 92,679,000 shares.
“`
